Abstract
Reverse Phase Protein Arrays (RPPA) represent a sensitive antibody-based proteomic approach, which enables simultaneous quantification of the abundance of multiple proteins and posttranslational modifications across multiple samples. Here, we provide protocols for RPPA performed on two distinct protein-binding substrates associated with two most commonly used RPPA platform technologies. We compare and contrast the respective advantages and limitations of each platform within the context of drug discovery applications.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Paweletz CP, Charboneau L, Bichsel VE et al (2001) Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 20(16):1981–1989
Pawlak M, Schick E, Bopp MA, Schneider MJ, Oroszlan P, Ehrat M (2002) Zeptosens' protein microarrays: a novel high performance microarray platform for low abundance protein analysis. Proteomics 2(4):383–393
Weissenstein U, Schneider MJ, Pawlak M et al (2006) Protein chip based miniaturized assay for the simultaneous quantitative monitoring of cancer biomarkers in tissue extracts. Proteomics 6(5):1427–1436
Boyd ZS, Wu QJ, O'brien C et al (2008) Proteomic analysis of breast cancer molecular subtypes and biomarkers of response to targeted kinase inhibitors using reverse-phase protein microarrays. Mol Cancer Ther 7(12):3695–3706
Voshol H, Ehrat M, Traenkle J, Bertrand E, Van Oostrum J (2009) Antibody-based proteomics: analysis of signaling networks using reverse protein arrays. FEBS J 276(23):6871–6879
Cardnell RJ, Feng Y, Diao L et al (2013) Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer. Clin Cancer Res 19(22):6322–6328
Girotti MR, Lopes F, Preece N et al (2015) Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma. Cancer Cell 27(1):85–96
Akbani R, Becker KF, Carragher N et al (2014) Realizing the promise of reverse phase protein arrays for clinical, translational, and basic research: a workshop report: the RPPA (reverse phase protein array) society. Mol Cell Proteomics 13(7):1625–1643
Cancer Genome Atlas Network (2012) Comprehensive molecular portraits of human breast tumours. Nature 490(7418):61–70
Mircean C, Shmulevich I, Cogdell D et al (2005) Robust estimation of protein expression ratios with lysate microarray technology. Bioinformatics 21(9):1935–1942
Nishizuka S, Charboneau L, Young L et al (2003) Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. Proc Natl Acad Sci U S A 100(24):14229–14234
Hu J, He X, Baggerly KA, Coombes KR, Hennessy BT, Mills GB (2007) Non-parametric quantification of protein lysate arrays. Bioinformatics 23(15):1986–1994
Troncale S, Barbet A, Coulibaly L et al (2012) NormaCurve: a SuperCurve-based method that simultaneously quantifies and normalizes reverse phase protein array data. PLoS One 7(6):e38686
Sun M, Lai D, Zhang L, Huang X (2015) Modified SuperCurve method for analysis of reverse-phase protein Array data. J Comput Biol 22(8):765–769
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Science+Business Media LLC
About this protocol
Cite this protocol
Macleod, K.G., Serrels, B., Carragher, N.O. (2017). Reverse Phase Protein Arrays and Drug Discovery. In: Lazar, I., Kontoyianni, M., Lazar, A. (eds) Proteomics for Drug Discovery. Methods in Molecular Biology, vol 1647. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-7201-2_10
Download citation
DOI: https://doi.org/10.1007/978-1-4939-7201-2_10
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-7200-5
Online ISBN: 978-1-4939-7201-2
eBook Packages: Springer Protocols